Matinas BioPharma gets NYSE American notice for failing stockholders’ equity listing standard

Matinas BioPharma Holdings, Inc.

Matinas BioPharma Holdings, Inc.

MTNB

0.00
  • Matinas BioPharma received an NYSE American non-compliance notice tied to continued listing equity standards under Sections 1003(a)(ii) and 1003(a)(iii).
  • Stockholders’ equity fell to $3.02 million as of March 31, 2026, below the $4 million minimum for issuers with recent multi-year losses.
  • Equity was $4.83 million as of Dec. 31, 2025, below the $6 million threshold tied to losses in the past five fiscal years.
  • NYSE American accepted its compliance plan, granting a cure period through Oct. 2, 2027, with quarterly monitoring.
  • Failure to regain compliance or meet plan milestones could trigger delisting proceedings, with appeal rights under NYSE American rules.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Matinas BioPharma Holdings Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202606261715PRIMZONEFULLFEED9753035) on June 26, 2026, and is solely responsible for the information contained therein.

This page is machine-translated. Sahm tries to improve but does not guarantee the accuracy and reliability of the translation, and will not be liable for any loss or damage caused by any inaccuracy or omission of the translation. *Disclaimer: The above content only represents the author's personal position and opinion and does not represent any position of Sahm Capital Financial Company and Sahm cannot confirm the authenticity, accuracy, and originality of the above content. Investors should consider the risks of investment products in light of their circumstances before making any investment decisions. When necessary, please consult a professional investment advisor. Sahm does not provide any investment advice, nor does it make any commitments and guarantees.